05.03.22
Stand J110
Kaneka’s probiotics and microbiome science affiliate, AB-BIOTICS, will share its latest scientific findings in natural probiotic strains that meet specific therapeutic needs and maintain human health.
The first ingredient to be showcased on stand includes the AB-BIOTICS AB21 four-strain probiotic formula – a novel probiotic formulated for viral respiratory infections. Following a clinical trial published in Gut Microbes, AB21 was shown to exhibit significant positive effects in COVID-19 outpatients, including reduction of viral load, duration of symptoms, and rate of remission.
The company will also showcase the postbiotic LipiGO, an ingredient extracted from specific strains previously used in the brewing process. Approved as a medical device for weight management, LipiGO acts in the gut, binds selectively to saturated fats, reducing their absorption and ensuring a safe weight loss. Three claims are approved when marketing LipiGO in the European Union: treatment of Type I obesity and overweight; reduction of the rebound effect after a diet; and reduction in the absorption of calories from dietary fat.
The company will also showcase its product i3.1, which is formulated for irritable bowel syndrome (IBS). This three-strain probiotic mix interacts with the pathogen S. sanguinis and works to improve intestinal permeability, reduce inflammation and support dysbiosis correction. According to the company, i3.1 is the only probiotic with clinically proven beneficial effects on visceral hypersensitivity, indicated by the World Gastroenterology Organisation in its Guidelines of Probiotics and Prebiotics.
Throughout the show, the AB-BIOTICS team of experts will be available on stand to discuss development opportunities that their patented strains can provide in therapeutic areas that include skin, cognitive, immune, cardiometabolic and pediatric health.
Kaneka’s probiotics and microbiome science affiliate, AB-BIOTICS, will share its latest scientific findings in natural probiotic strains that meet specific therapeutic needs and maintain human health.
The first ingredient to be showcased on stand includes the AB-BIOTICS AB21 four-strain probiotic formula – a novel probiotic formulated for viral respiratory infections. Following a clinical trial published in Gut Microbes, AB21 was shown to exhibit significant positive effects in COVID-19 outpatients, including reduction of viral load, duration of symptoms, and rate of remission.
The company will also showcase the postbiotic LipiGO, an ingredient extracted from specific strains previously used in the brewing process. Approved as a medical device for weight management, LipiGO acts in the gut, binds selectively to saturated fats, reducing their absorption and ensuring a safe weight loss. Three claims are approved when marketing LipiGO in the European Union: treatment of Type I obesity and overweight; reduction of the rebound effect after a diet; and reduction in the absorption of calories from dietary fat.
The company will also showcase its product i3.1, which is formulated for irritable bowel syndrome (IBS). This three-strain probiotic mix interacts with the pathogen S. sanguinis and works to improve intestinal permeability, reduce inflammation and support dysbiosis correction. According to the company, i3.1 is the only probiotic with clinically proven beneficial effects on visceral hypersensitivity, indicated by the World Gastroenterology Organisation in its Guidelines of Probiotics and Prebiotics.
Throughout the show, the AB-BIOTICS team of experts will be available on stand to discuss development opportunities that their patented strains can provide in therapeutic areas that include skin, cognitive, immune, cardiometabolic and pediatric health.
